Phase II study of high-dose methotrexate in the treatment of patients with non-small cell carcinoma of the lung: An Eastern Cooperative Oncology Group Study

D. S. Ettinger, K. E. Stanley, J. S. Nystrom

Research output: Contribution to journalArticlepeer-review

Abstract

Twenty-eight patients with inoperable non-small cell carcinoma of the lung were treated with high-dose methotrexate with citrovorum factor rescue. One patient (4%) responded with a partial regression of the tumor. Three patients had severe or life-threatening complications: acute renal failure, acute shortness of breath, and bone marrow suppression, respectively. There is 98% confidence that the true response rate for this therapy is <20%. The results of this study demonstrate that high-dose methotrexate with citrovorum factor rescue, in the schedule utilized, is not effective in the treatment of patients with non-small cell carcinoma of the lung.

Original languageEnglish (US)
Pages (from-to)1017-1021
Number of pages5
JournalCancer treatment reports
Volume64
Issue number10-11
StatePublished - 1980

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II study of high-dose methotrexate in the treatment of patients with non-small cell carcinoma of the lung: An Eastern Cooperative Oncology Group Study'. Together they form a unique fingerprint.

Cite this